A YORK regenerative medical device company is targeting the fast-growing market for soft-tissue knee repairs after receiving positive results in pre-clinical studies.
Clinical studies can now begin in Europe following a regulatory review of Tissue Regenix’s patented dCell formula of “washing” the DNA from animal tissues to enable them to form a scaffold which can be used in human transplants.
The pre-clinical study indicated the device was safe with no adverse or inflammatory responses, and there were signs of cells starting to integrate the scaffold into the existing tissue.
Antony Odell, managing director, said: “This important piece of safety data allows us to continue to move towards the clinical evaluation of the dCELL meniscus, which will be the pivotal study to enable EU regulatory approval so this approach can deliver real benefits to patients."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here